BMI View: Pressure to increase premiums charged for Indonesia's universal healthcare scheme will remain
as it struggles with financial stability. Financial subsidies from the government to support the programme
will alleviate but not fully address the challenge, due t ..."
BMI View: The Indonesian medical landscape will see a larger presence of private healthcare providers
over medium term. Underpinning this expansion is the robust prospects for the industry, with the
introduction of a Coordination of Benefits scheme allowing patients t ..."
BMI View: The challenges facing domestic pharmaceutical firms in Indonesia will continue. While efforts
to alleviate the country's reliance on pharmaceutical raw material imports are underway, these are unlikely
to have a substantial impact until 2017. Moreover, the a ..."
BMI View: Foreign exchange pressures will be a key factor influencing the strategies of Indonesia
drugmakers. In particular, the need to reduce their reliance on the import of pharmaceutical ingredients has
been accentuated in 2015 as the depreciating rupiah erodes pr ..."
BMI View: We hold a bullish outlook for private healthcare providers in Indonesia. Central to this view is
the long-term rise of household incomes - a boon for private hospitals which generates a substantial
amount of their revenue from out-of-pocket payments. In addi ..."
BMI View: Indonesia's healthcare expenditure will grow robustly. Key to this trajectory is rising household
incomes which will have strong positive ramifications due to the dominant role of private spending as a
source of healthcare financing. This will be further aug ..."
BMI View: Generic drugs sales in Indonesia will continue to see significant growth as they remain
favoured by both low per capita pharmaceutical spending and inadequate intellectual property protection
in the country. This is further reinforced by a growing chronic di ..."
BMI View: Indonesia's pharmaceutical market holds strong promise due to the continued expansion of
universal healthcare and positive economic outlook with the ongoing integration of the country into the
ASEAN Economic Community. However, this potential is weighed on b ..."
BMI View: Indonesia is one of the most promising markets for the pharmaceutical and healthcare
companies in South East Asia. The country's large population, positive economic outlook and considerable
disease burden bode well for growth in demand for drugs, medical devices and h ..."
BMI View: While the implementation of universal health coverage will benefit the general population
through increased access to medical services, we highlight the need to evaluate whether existing health
facilities have the capacity to handle more patients.